Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Buy” from Analysts

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has received a consensus recommendation of “Buy” from the five analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $12.38.

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a report on Tuesday, January 14th.

Corvus Pharmaceuticals Price Performance

CRVS opened at $4.72 on Tuesday. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00. The business has a 50-day moving average of $4.84 and a two-hundred day moving average of $6.09. The stock has a market capitalization of $303.29 million, a price-to-earnings ratio of -5.08 and a beta of 0.91.

Institutional Trading of Corvus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Avity Investment Management Inc. lifted its position in Corvus Pharmaceuticals by 7.6% during the fourth quarter. Avity Investment Management Inc. now owns 29,680 shares of the company’s stock valued at $159,000 after buying an additional 2,100 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Corvus Pharmaceuticals by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 566,863 shares of the company’s stock valued at $3,034,000 after acquiring an additional 3,854 shares in the last quarter. Renaissance Technologies LLC boosted its position in Corvus Pharmaceuticals by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 390,688 shares of the company’s stock worth $2,090,000 after purchasing an additional 4,100 shares during the period. Nwam LLC increased its holdings in Corvus Pharmaceuticals by 54.2% in the 4th quarter. Nwam LLC now owns 15,500 shares of the company’s stock valued at $83,000 after purchasing an additional 5,450 shares in the last quarter. Finally, Virtus ETF Advisers LLC purchased a new position in Corvus Pharmaceuticals in the fourth quarter valued at about $47,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.